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Abstract
OBJECTIVE: To study the effect of Lichong decoc-
tion (LD) on expression of matrix metalloprotein-
ase-2 (MMP-2) and metalloproteinase-2 (TIMP-2) in
a rat model of uterine leiomyoma (UL).
METHODS: UL was induced in rats using exoge-
nous estrogen and progesterone. LD was adminis-
tered (p.o.) for 4 weeks, and mifepristone (RU-486)
used as a control. To observe the effect of LD on
the uterine coefficient and uterine transverse diam-
eter, a radioimmunoassay method was used to de-
tect serum levels of sex hormones. Light microscop-
ic analyses of pathologic changes in the tissues of
UL rats were evaluated. Expression of the proteins
of matrix metalloproteinases (MMPs) and tissue in-
hibitors of metalloproteinases (TIMPs) in uterine tis-
sues was assessed by immunohistochemical stain-
ing and western blotting.
RESULTS: A UL model in rats was established suc-
cessfully. LD reduced uterine weight, uterine coeffi-
cient, and uterine transverse diameter compared
with untreated controls. LD reduced levels of estra-
diol, progesterone, follicle-stimulating hormone,
and luteinizing hormone in our UL models. LD im-
proved the pathologic condition of uterine muscle.
Expression of MMP-2 protein decreased to varying
extents in LD-treated groups, but TIMP-2 levels were
enhanced. LD appears to reduce MMP-2 expression
and increase TIMP-2 expression in UL tissue.
CONCLUSION: These data suggest that the mecha-
nism of action of LD on ULs may involve reduction
of MMP-2 expression and increase in TIMP-2 expres-
sion in rats.
Key words: Leiomyoma; Matrix metalloproteinase
2; Tissue inhibitor of metalloproteinase-2; Lichong
decoction
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INTRODUCTION
Uterine leiomyomas (ULs; also known as "uterine fi-
broids") grow via hyperplasia of uterine smooth mus-
cle. ULs are a common benign tumor in the female re-
productive system. Main manifestations of ULs are ab-
dominal masses, depressive symptoms, pain, infertility,
spontaneous abortion, menstrual disorders, and dys-
menorrhea.1
Traditional Chinese Medicine infers that the pathogen-
esis of UL is "blood stasis" caused by a disorder of vis-
cera, hindrance in the functional activities of Qi, and
internal static blood obstruction. ULs have a long
course, which damages healthy Qi and leads to other
diseases and deficiency syndromes.2 Deficiency of vital
Qi is the basis of ULs, whereas blood stasis is the exter-
nal manifestation. Recently, this pathogenesis has been
treated by strengthening body resistance and eliminat-
ing blood stagnation. This is a suitable and viable meth-
od to cure ULs that is now used widely.
Lichong decoction (LD) is documented in Yi Xue
Zhong Zhong Can Xi Lu,3 written by a famous physi-
cian in the Qing Dynasty: Zhang Xichun. The formula
used to prepare the decoction is Huangqi (Radix Astrag-
ali Mongolici), Dangshen (Radix Codonopsis), Baizhu
(Rhizoma Atractylodis Macrocephalae), Shanyao (Rhi-
zoma Dioscoreae Oppositae), Tianhuafen (Radix Tricho-
santhis), Zhimu (Rhizoma Anemarrhenae), Sanleng
(Rhizoma Sparganii), Ezhu (Rhizoma Curcumae Phaeo-
caulis), and Jineijin (Endothelium Coreneum Gigeriae
Galli). This formula was designed to treat ULs by
strengthening healthy Qi, enhancing blood flow, and
eliminating pathogens.
Our research team has revealed that LD can significant-
ly suppress UL growth, and trigger apoptosis of UL
cells.4 Research has also shown that the prevalence and
development of ULs are related to an imbalance in the
metabolism of the extracellular matrix (ECM). Also,
ECM degradation appears to be a signal for tumor cells
to attack and migrate into normal tissue. ECM degra-
dation is dependent upon the ratio of matrix metallo-
proteinases (MMPs) to their endogenous inhibitors: tis-
sue inhibitors of metalloproteinases (TIMPs). An im-
balance in expression of MMP-2 and TIMP-2 has a
key role in this process.6
We established a rat model of ULs to study further the
effect of LD on expression of MMP-2 and TIMP-2,
and to investigate its possible mechanism of action.
MATERIALS ANDMETHODS
Experimental animals
Homologous, healthy, adult, female, specific patho-
gen-free Sprague-Dawley rats [n = 50; 3 months; (200
± 20) g] were provided by Beijing Weitong Lihua Ex-
perimental Animal Tech (Beijing, China). Rats were
kept in the Center of Laboratory Animals at our uni-
versity. After adaptive feeding for 1 week, rats were di-
vided into five groups of ten using the random num-
bers method: normal control (N); model (M); mifepris-
tone (Ru-486, R); low-dose LD (LLD); high-dose LD
(HLD). The study protocol was approved by the Eth-
ics Committee of Capital Medical University (Beijing,
China).
Drugs and reagents
LD was prepared according to standard procedures. All
Chinese herb ingredients were purchased from Beijing
Tongrentang Drug Store (Beijing, China). Mifepris-
tone (Ru-486) was obtained from Zhejiang Fairy Ju
Pharmaceuticals (Zhejiang, China). Estradiol benzoate
was purchased from Tianjin Jin Yao Amino Acids
(Tianjin, China). Progesterone was obtained from
Shanghai General Pharmaceuticals (Shanghai, China).
Rabbit polyclonal anti-MMP-2 kits and rabbit poly-
clonal anti-TIMP-2 kits were from Wuhan Boster Bio-
logical Engineering (Wuhan, China). Rabbit streptavi-
din-horseradish peroxidase (HRP) kits were purchased
from Kangwei Biological Technology (Beijing, China).
HRP-labeled goat anti-rabbit IgG was obtained from
Jackson (Jackson, MI, USA), as was HRP-labeled goat
anti-rat IgG. HRP-labeled glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was purchased from Shang-
hai Kang Cheng Biological (Shanghai, China). Mouse
TIMP-2 was obtained from Abcam (Cambridge, UK).
Rabbit MMP-2 was from CST (Boston, MA, USA).
Induction of a rat model of UL and treatments
A rat model of UL was established based on previous
reports.7,8 Rats received estrogen (0.5 mg/kg body
weight, i.p.) once daily for the first 4 weeks, followed
by estrogen and progesterone at an identical dose and
via the same route for 5 days. The LLD dose was equiv-
alent to an adult dose (10.15 g·kg－1·d－1), whereas the
HLD dose was three-times the adult dose (30.45 g·kg－1·
d－1). The dose administered to rats in the R group was
equivalent to the dose for adults (2.92mg·kg－1·d－1). Rats
in N and M groups were gavaged with an equivalent
volume of water once daily for the final 4 weeks. Drugs
used in this process were stored at 4℃.
Radioimmunoassay (RIA) used to detect serum levels
of sex hormones
Serum levels of sex hormones in groups were assessed
using a RIA. Blood samples were taken via cardiac
puncture for RIA analyses one day after treatment had
been completed. Serum was separated using commer-
cial kits according to manufacturer instructions.
Calculation of the uterine coefficient (UC) and
uterine transverse diameter (UTD)
The general status of rats was recorded. Then, rats were
killed and blood samples taken. The uterus was
weighed and uterine wet weight (mg) recorded. Angles
at several points above the cervix and at the uterus root
were measured (mm) using vernier calipers to assess its
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diameter. The UC was calculated using the following
formula:
UC (mg/g) = uterus weight (mg) / rat body weight (g)
The UTD (mm) was measured using vernier calipers at
points on the uterus above the cervix and under the an-
gle of the root diameter (side angle of the uterus root).
Pathologic changes in UL tissue as seen under light
microscopy
Five rats from each group were used for hematoxylin &
eosin (H & E) staining and immunohistochemical
analyses. UL tissue was fixed, embedded and sectioned.
Sections were stained with H & E and observed using
a light microscope (Eclipse 80i; Nikon, Tokyo, Japan).
Immunohistochemical staining of expression of
MMP-2 and TIMP-2 in UL tissue
UL tissues under the left corner and right angle of the
uterine root were obtained, fixed in 10% formalde-
hyde, dehydrated, embedded in paraffin, and sectioned
(Kangwei Biological Technology). In all samples, paraf-
fin-embedded sections prepared by dewaxing and hy-
dration, and antigen repair could be detected using rab-
bit streptavidin-HRP kits (Kangwei Biological Technol-
ogy Company, Beijing, China). After staining with 3,
3′-Diaminobenzidine and hematoxylin re-staining
(Kangwei Biological Technology Company, Beijing,
China), 1% hydrochloric acid solution (Kangwei Bio-
logical Technology Company, Beijing, China) was used
for 10 s, followed by rinsing with phosphate-buffered
saline and dehydration. Then, images were recorded us-
ing a microscopic imaging system. Each animal was se-
lected randomly and evaluated according to the ran-
dom numbers method in a double-blind manner ac-
cording to the following criteria: "negative", "weakly
positive", "positive", and "strongly positive". These
four grades were separated and calculated for every
group. Prevalence of positive expression of MMP-2
and TIMP-2 was calculated.
Western blotting of the expression and protein
content of MMP-2 and TIMP-2 in UL tissue
UL tissue under the right corner and left angle of the
root were obtained, frozen in liquid nitrogen, and
stored at － 80 ℃ . Tissues were homogenized with
phenylmethanesulfonyl fluoride, centrifuged (1006.2
× g, 20 min), and the clear supernatant collected. Pro-
tein concentrations were measured according to the in-
structions of a Bicinchoninic Acid Protein Assay kit
(Bio-Rad Company, Hercules, CA, USA), so that pro-
tein transformation could be assessed. Separation gels
(12% and 8%) and a spacer gel (5%) were prepared ac-
cording to the molecular weight of the protein. Mem-
branes were observed using electrophoresis and wet
transfer method. Incubation with primary and second-
ary antibodies was done according to manufacturer in-
structions. An electrochemiluminescence assay was un-
dertaken after membranes had been washed, and then
they were stained for 3-5 min. Membranes were ex-
posed to film from 10 s to 5 min, developed for 2 min,
and fixed. GAPDH was used as the internal standard.
Western blotting was done in triplicate at least.
Statistical analyses
Data are the mean ± standard error and analyzed using
SPSS v13.0 (IBM, Armonk, NY, USA). Differences
among groups were tested with one-way analysis of
variance with a post hoc least significant difference test
or a rank-sum test. P < 0.05 was considered significant.
RESULTS
Basic condition of rats
Initially, rats were in good health, ate and drank nor-
mally, had white and glossy fur, and were responsive
and unstressed. After the UL model had been created,
rats were stressed and easily startled, their fur became
yellow and they had severe depilation.
UC and UTD
Differences in the UC and UTD between group M
and group N would inform us if the UL model had
been developed. Observation of the differences be-
tween the M group and other groups suggested that
LD could reduce the UC of fibroids and narrowing of
fibroids in the rat uterus (Table 1).
Table 1 shows that the UC and UTD of the M group
increased compared with those in the N group (P <
Table 1 Uterine coefficient and uterine transverse diameter in rats for each group ( xˉ ± s)
Group
N
M
HLD
LLD
R
n
10
10
10
10
10
UC (mg/g)
3.11±0.37a
9.80±0.33b
5.42±0.38a
4.37±0.60a
5.73±0.27a
UTD (mm)
Points under the angle of the diameter
7.20±0.59a
13.85±0.88b
10.50±0.97a
9.25±0.92a
11.05±0.64a
Angle of root diameter (side)
4.25±0.35a
8.25±0.82b
4.85±0.71a
4.80±0.71a
5.05±0.72a
Notes: N: normal control group (did not use drugs); M: model group (did not use drugs); HLD: high-dose Lichong decoction group
(30.45 g·kg－ 1·d－ 1, 4 weeks); LLD: low-dose Lichong decoction group (10.15 g·kg－ 1·d－ 1, 4 weeks); R: mifepristone (Ru-486) group
(2.92 mg·kg－ 1·d－ 1, 4 weeks). UC: uterine coefficient; UTD: uterine transverse diameter. Compared with the model group, aP < 0.01;
compared with the normal group, bP < 0.01.
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0.01). The UL model was developed successfully. The
UC in rats of all treatment groups was reduced to some
extent, with the UTD narrowing and changing the
most in the LLD group compared with the M group
(P < 0.01).
Serum levels of sex hormones
Serum levels of the sex hormones estradiol (E2), proges-
terone, follicle-stimulating hormone (FSH), and lutein-
izing hormone (LH) were compared between different
groups (Table 2). E2 levels increased significantly in the
M group compared with those in the N group (P <
0.01). E2 levels in HLD and LLD groups decreased sig-
nificantly compared with those in the N group (P <
0.01). E2 levels in the R group decreased significantly
compared with those in the N group (P < 0.01). Pro-
gesterone levels in the M group were elevated signifi-
cantly compared with those in the N group (P < 0.01).
Compared with the M group, progesterone levels in
the HLD group and R group were reduced significant-
ly (P < 0.01). There was no significant difference be-
tween LLD and M groups (P > 0.05).
Compared with the N group, FSH levels in the M
group increased significantly (P < 0.01). FSH levels in
the HLD group were reduced significantly compared
with those in the M group (P < 0.01). There was no
difference between the M group and HLD or R
groups.
Compared with the N group, LH levels in the M
group increased significantly (P < 0.01). Compared
with the M group, LH levels in the LLD group de-
creased significantly (P < 0.05). LH levels in the R
group decreased significantly compared with those in
the M group (P < 0.01). There was no difference in
HLD compared with the M group.
Table 2 reveals that progesterone levels were changed,
suggesting that a rat model of UL had been created suc-
cessfully. LD could reduce levels of estrogen and pro-
gesterone in the rat model of UL.
Pathologic changes in UL tissue
The uterine smooth muscle layer (SML) in N-group
rats was thin, smooth muscle cells (SMCs) were slen-
der, and the inner and outer longitudinal muscles
were arranged in orderly rows. The uterine SML of
M-group rats was thick, muscle cells were arranged
randomly, the inner muscle and outer longitudinal
muscle were disorganized, and the nucleus had in-
creased in size, showing a short fusiform or round
shape, clear nucleoli, and marked hyperplasia of con-
nective tissue. The SML in the HLD group was
thin, SMCs were slender, the inner muscle and outer
longitudinal muscle were arranged in orderly rows,
and the nucleus of the fusiform or rod-shaped nucle-
olus was not clear. The SML (including SMCs) in
the LLD group was very thin, SMCs were slender,
the inner muscle and outer longitudinal muscle were
arranged in orderly rows, and the nucleus of the fusi-
form or rod-shaped nucleolus was not clear. The
SML of the R group was thick, and SMCs were
slender, the inner muscle and outer longitudinal mus-
cle were arranged in orderly rows, but a small
amount of connective-tissue proliferation could be
seen, and the fusiform or rod-shaped nucleus in the
nucleolus was not clear. Effects of pathologic changes
in this UL model suggested that the model had been
established successfully. The pathology showed that
LD improved the condition of uterine muscle (Fig-
ure 1).
Table 2 Serum levels of sex hormones in rats for each group ( xˉ ± s, mmol/L)
Group
N
M
HLD
LLD
R
n
10
10
10
10
10
Estradiol
15.1±1.1a
26.8±1. 8
14.4±2.3a
18.8±1.7a
18.4±2.2a
Progesterone
2.4±0.4a
3.1±0.6
2.3±0.4a
3.0±0.6
2.3±0.7a
Follicle-stimulating hormone
22.1±1.4a
25.7±2.0
24.2±1.8
22.5±2.7a
25.3±1.3
Luteinizing hormone
2.7±0.4a
3.5±0.6
3.0±0. 5
2.9±0.8b
2.2±0.4a
Notes: N: normal control group (did not use drugs); M: model group (did not use drugs); HLD: high-dose Lichong decoction group
(30.45 g·kg－ 1·d－ 1, 4 weeks); LLD: low-dose Lichong decoction group (10.15 g·kg－ 1·d－ 1, 4 weeks); R: mifepristone (Ru-486) group
(2.92 mg·kg－1·d－1, 4 weeks). Compared with the model group, aP < 0.05, bP < 0.01.
A B C D E
Figure 1 Pathologic changes in Uterine Leiomyoma tissues (HE staining, × 200)
A: normal control group (did not use drugs); B: model group (did not use drugs); C: HLD group (high-dose Lichong decoction
group, 30.45 g·kg－1·d－1, 4 weeks); D: LLD group (low-dose Lichong decoction group, 10.15 g·kg－1·d－1, 4 weeks); E: R group (mife-
pristone group, 2.92 mg·kg－1·d－1, 4 weeks). HE: hematoxylin and eosin.
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MMP-2 expression in UL tissue
Semi-quantitative analyses were based on the amount
of staining, the intensity of which was: "negative" (not
colored or the same as the background color), 0 points;
"weakly colored", 1 points, "weak-to-strong intensity",
2 points; "strongly dyed", 3 points.
MMP-2 was expressed mainly in the cytoplasm and
rarely in the nucleus. The cytoplasm was stained brown
and sepia. Prevalence of positive expression of MMP-2
was significantly higher in the M group, but lower in
HLD, LLD and R groups, compared with the N group
(Figure 2).
MMP-2 expression was higher in the M group than in
the N group (P < 0.01), but it was lower in HLD and
LLD groups compared with the M group (P < 0.01).
MMP-2 expression in the R group was lower than that
in the M group (P < 0.01) (Table 3).
TIMP-2 expression in UL tissue
TIMP-2 expression was mainly in the cytoplasm and
rarely in the nucleus. The cytoplasm was stained brown
and sepia. TIMP-2 expression was significantly lower
in the M group compared with the N group (P <
0.01). TIMP-2 expression was higher in HLD, LLD,
and R groups compared with those in the M group
(Figure 3).
TIMP-2 expression in the M group was lower than
that in the N group (P < 0.01). TIMP-2 expression in
HLD and LLD groups was higher than that in the M
group (P < 0.01). There was no difference inTIMP-2 ex-
pression between the R group and M group (Table 4).
Expression and protein content of MMP-2 and
TIMP-2 in UL tissue
MMP-2 expression in the M group was significantly
higher than that in the N group (P < 0.01). MMP-2
expression was significantly lower in the HLD group
(P < 0.05) and in LLD and R groups compared with
the M group (P < 0.01). TIMP-2 expression in the M
group was lower than that in the N group (P < 0.01).
A B C D E
Figure 2 Effect of Lichong decoction on Matrix Metalloproteinases expression in Uterine Leiomyoma tissues (SP, × 200)
A: normal control group (did not use drugs); B: model group (did not use drugs); C: HLD group (high-dose Lichong decoction
group, 30.45 g·kg－1·d－1, 4 weeks); D: LLD group (low-dose Lichong decoction group, 10.15 g·kg－1·d－1, 4 weeks); E: R group (mife-
pristone group, 2.92 mg·kg－1·d－1, 4 weeks). SP: streptavidin perosidase.
A B C D E
Figure 3 Effect of Lichong decoction on Matrix Metalloproteinases expression in Uterine Leiomyoma tissue (Streptavidin-Perosi-
dase × 40)
A: normal control group (did not use drugs); B: model group (did not use drugs); C: HLD group (high-dose Lichong decoction
group, 30.45 g·kg－1·d－1, 4 weeks); D: LLD group (low-dose Lichong decoction group, 10.15 g·kg－1·d－1, 4 weeks); E: R group (mife-
pristone group, 2.92 mg·kg－1·d－1, 4 weeks).
Table 3 Matrix Metalloproteinases-2 expression in uterine tis-
sue for each group (rank sum test)
Group
N
M
HLD
LLD
R
n
10
10
10
10
10
–
0
0
0
0
0
+
8
0
3
5
4
++
2
2
6
4
5
+++
0
8
1
1
1
Notes: N: normal control group (did not use drugs); M: model
group (did not use drugs); HLD: high-dose Lichong decoction
group (30.45 g·kg－1·d－1, 4 weeks); LLD: low-dose Lichong de-
coction group (10.15 g·kg－ 1·d－ 1, 4 weeks); R: mifepristone
(Ru-486) group (2.92 mg·kg－ 1·d－ 1, 4 weeks). N vs M group,
P < 0.01; HLD vs M group, P < 0.01; LLD vs M group, P <
0.01; R vsM group, P < 0.01.
Table 4 Matrix Metalloproteinases-2 expression in uterine tis-
sue for each group (rank sum test)
Group
N
M
HLD
LLD
R
n
10
10
10
10
10
–
0
0
0
0
0
+
0
8
3
2
6
++
2
2
1
3
3
+++
8
0
6
5
1
Notes: N: normal control group (did not use drugs); M: model
group (did not use drugs); HLD: high-dose Lichong decoction
group (30.45 g·kg－1·d－1, 4 weeks); LLD: low-dose Lichong de-
coction group (10.15 g·kg－ 1·d－ 1, 4 weeks); R: mifepristone
(Ru-486) group (2.92 mg·kg－ 1·d－ 1, 4 weeks). N vs M group,
P < 0.01; HLD vs M group, P < 0.01; LLD vs M group, P <
0.01; R vsM group, P > 0.05.
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TIMP-2 expression in HLD, LLD, and R groups was
higher than that in the M group (P < 0.01), (Figure 4,
5, Table 5).
DISCUSSION
More than 50% of UL tissues comprise the ECM
(basement membrane and matrix).7,10 Healthy base-
ment membranes should contain type-IV collagen,
laminin, and fibronectin.10 Studies have shown that al-
terations and imbalances in ECM components have a
profound effect upon cell function.11,12 ECM degrada-
tion is an important way for tumor cells to invade nor-
mal tissues and initiate migration.13 MMPs are
zinc-containing enzymes that are closely related to the
ECM. They play an important part in embryonic de-
velopment. Tumor cells destroy the basement mem-
brane and ECM organization when they start to mi-
grate. MMPs are the only known enzymes that can de-
grade collagen fibers.14 MMPs hydrolyze the ECM, and
their expression increases during tumor metastasis; in
this manner, MMPs are closely related to tumor metas-
tasis.15 MMPs have several roles in tumorigenesis and
metastasis: (a) destruction of local tissue structure and
promotion of tumor growth; (b) destruction of the bar-
rier of the basement membrane, thereby making condi-
tions conducive to tumor metastasis; (c) rebuilding of
the ECM to promote tumor angiogenesis. In health,
MMP expression is low but, during growth, cell fac-
tors, physical/chemical stimuli, and malignant transfor-
mation cause conditions that increase its expression.16
TIMPs are endogenous MMP inhibitors that partici-
pate in MMP activity and regulate ECM organization
locally.17,18 TIMPs play an important part in the bal-
ance of degradation of MMP substrates, and are closely
related to the proliferation, migration, invasion, and
apoptosis of tumor cells.19 MMP-2 and MMP-9 have
direct and important roles in tumor metastasis because
they can specifically degrade the ECM and main com-
ponents of the basement membrane: type-IV collagen
fibers.12
TIMP-2 can inhibit the activity of all MMPs, but it
has the highest affinity for MMP-2. Other TIMPs can
inhibit neovascularization, hinder movement of the
MMPs that mediate endothelial cells, and inhibit re-
lease of factors that promote angiogenesis in the ECM
to prevent ECM degradation.20
In conclusion, by nourishing healthy Qi and eliminat-
ing blood stasis, LD can inhibit SMC proliferation in
the rat uterus. LD can reduce the UC of fibroids in the
rat uterus, narrow their width, and reduce their num-
ber uterine. LD significantly reduces serum levels of
sex hormones. LD can also regulate ECM-degrading
enzymes by reducing MMP-2 expression and increas-
ing TIMP-2 expression. This mechanism of action may
involve the balance of the MMP-TIMP system. LD
may also control degradation of type-Ⅳ collagen specif-
ically to regulate ECM metabolism and inhibit UL de-
Group
N
M
HLD
LLD
R
n
6
6
6
6
6
MMP-2
0.84±0.10a
1.15±0.21
0.97±0.11b
0.69±0.16a
0.86±0.14a
TIMP-2
1.28±0.26a
0.53±0.16
1.15±0.22a
1.54±0.36a
1.45±0.37a
Notes: N: normal control group (did not use drugs); M: model
group (did not use drugs); HLD: high-dose Lichong decoction
group (30.45 g·kg－1·d－1, 4 weeks); LLD: low-dose Lichong de-
coction group (10.15 g·kg－ 1·d－ 1, 4 weeks); R: mifepristone
(Ru-486) group (2.92 mg·kg－1·d－1, 4 weeks). Compared with
the model group, aP < 0.01, bP < 0.05. MMP-2: matrix metallo-
proteinase-2; TIMP-2: metalloproteinase-2;
Table 5 Effects of LD on expression of Matrix Metalloprotein-
ases-2 and Matrix Metalloproteinases-2 protein in UL tissues
( xˉ ± s)
TIMP2
GAPDH
kDa
29
36
1 2 3 4 5
Figure 5 Effect of LD on the Matrix Metalloproteinases pro-
tein content in UL tissue
1: Normal group (did not use drugs); 2: Model control group
(did not use drugs); 3: HLD group (high-dose Lichong decoc-
tion group, 30.45 g·kg － 1·d － 1, 4 weeks); 4: LLD group
(low-dose Lichong decoction group, 10.15 g·kg－ 1·d－ 1, 4
weeks); 5: R group (mifepristone group, 2.92 mg·kg－1·d－1, 4
weeks). UL: uterine leiomyoma; TIMP-2: metalloprotein-
ase-2; GAPDH: glyceraldehyde-3-phosphate dehydroge-
nase; LD: Lichong decoction.
MMP-2
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kDa
72
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1 2 3 4 5
Figure 4 Effect of LD on Matrix Metalloproteinases protein
content in UL tissue
1: normal group (did not use drugs); 2: model control group
(did not use drugs); 3: HLD group (high-dose Lichong decoc-
tion group, 30.45 g·kg － 1·d － 1, 4 weeks); 4: LLD group
(low-dose Lichong decoction group, 10.15 g·kg－ 1·d－ 1, 4
weeks); 5: R group (mifepristone group, 2.92 g·kg－1·d－1, 4
weeks). UL: uterine leiomyoma. MMP-2: matrix metallopro-
teinase-2; GAPDH: glyceraldehyde-3-phosphate dehydroge-
nase; LD: Lichong decoction.
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velopment. Thus, LD may have a role in protection of
the uterus, as well as prevention and treatment of ULs,
but its detailed role and mechanism of action require
further study.
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